Rakovina Therapeutics Inc. (RKV.V)
| Previous Close | 0.1450 |
| Open | 0.1300 |
| Bid | 0.1250 x N/A |
| Ask | 0.1600 x N/A |
| Day's Range | 0.1300 - 0.1600 |
| 52 Week Range | 0.1000 - 0.2500 |
| Volume | |
| Avg. Volume | 12,865 |
| Market Cap | 11.169M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Apr 25, 2023 - May 01, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Rakovina Therapeutics Announces Presentation at the 6th Annual DDR-inhibitors Summit
VANCOUVER, British Columbia, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), is pleased to announce a scientific presentation at the 6th Annual DDR Inhibitors Summit in Boston, MA. The 6th Annual DDR Inhibitors Summit, held in Boston January 24-26, 2023, brought together academic and pharmaceutical industry researchers to share progress across the preclinical and clinical DDR inhibitor landscape. The conference aims to provide an up-to-date overview of
- GlobeNewswire
Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022
VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies, is pleased to announce that it has been invited to present at the Emerging Growth Conference on Wednesday, November 30, 2022, at 10:15am Eastern standard time. Rakovina invites individual and institutional investors as well as advisors and
- GlobeNewswire
Rakovina Therapeutics Inc. Announces Q3 2022 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for the quarter ended September 30, 2022 and provided a corporate update. Corporate Update Rakovina Therapeutics has continued to communicate progress in the Company’s research and development programs through presentations at pee
